REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Skin Glow & Hair Density

Skin & Hairintermediate
37
Share
Peptides

3

Avg Daily mcg

3,250

Level

intermediate

Added

May 16, 2026

Overview

The Skin Glow and Hair Density stack is an intermediate-level aesthetic protocol that targets the biological mechanisms underlying skin radiance, elasticity, and hair follicle vitality. Rather than masking cosmetic concerns topically, this stack works at the cellular level to restore youthful gene expression patterns and promote robust collagen and keratin production. GHK-Cu, administered at 500mcg daily, is the primary driver of visible skin and hair improvements in this protocol. This naturally occurring copper peptide declines significantly with age and has been shown in research to reset gene expression in fibroblasts to a more youthful pattern. It stimulates collagen I, III, and V synthesis, increases elastin production, promotes glycosaminoglycan synthesis for improved skin hydration, and enhances hair follicle size and proliferative capacity. Studies have demonstrated GHK-Cu can increase hair follicle cell proliferation by up to 70 percent while simultaneously improving skin thickness and firmness. Epithalon, dosed at 5000mcg every other day, addresses skin and hair aging at the chromosomal level by activating telomerase in somatic cells. As cells divide throughout life, telomere shortening signals senescence, causing visible aging of skin and hair. Epithalon counteracts this by maintaining telomere length, effectively extending the replicative lifespan of dermal fibroblasts, keratinocytes, and hair follicle stem cells. Research in cell culture models has shown telomerase activation can reverse markers of cellular aging, translating to improved skin texture and hair growth cycles. BPC-157 at 250mcg daily supports the stack by enhancing blood vessel formation in the dermis and scalp. Improved microcirculation delivers more oxygen and nutrients to skin cells and hair follicles, creating optimal conditions for the regenerative effects of GHK-Cu and Epithalon to manifest visibly. This protocol is suited for individuals experiencing age-related skin thinning, loss of radiance, fine lines, or diffuse hair thinning. It works best as an 8-12 week cycle with visible improvements typically appearing by weeks 4-6. Morning administration of all peptides is recommended. For enhanced results, pair with adequate protein intake, vitamin C supplementation, and sun protection.

Dosing Protocol

500 mcg

per dose

Epithalon

Every other day

Read more about Epithalon →

5,000 mcg

per dose

250 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.